Pretreatment Voiding Volume as a Predictor of Post-brachytherapy Urinary Quality of Life in Patients With Prostate Cancer: A Retrospective Study.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
193 patients with localized prostate cancer who underwent brachytherapy at our institution.
I · Intervention 중재 / 시술
brachytherapy at our institution
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Conclusion Preoperative voiding volume was significantly associated with changes in post-treatment urination-related QOL. These findings suggest that preoperative urination-related parameters may help predict post-treatment QOL, highlighting the importance of evaluating pretreatment urinary function when selecting treatments for patients with localized prostate cancer.
Introduction This study was performed to investigate the relationship between changes in urination-related quality of life (QOL) after brachytherapy and preoperative findings, including urinary functi
APA
Wakita N, Teishima J, et al. (2025). Pretreatment Voiding Volume as a Predictor of Post-brachytherapy Urinary Quality of Life in Patients With Prostate Cancer: A Retrospective Study.. Cureus, 17(9), e91946. https://doi.org/10.7759/cureus.91946
MLA
Wakita N, et al.. "Pretreatment Voiding Volume as a Predictor of Post-brachytherapy Urinary Quality of Life in Patients With Prostate Cancer: A Retrospective Study.." Cureus, vol. 17, no. 9, 2025, pp. e91946.
PMID
41080390 ↗
Abstract 한글 요약
Introduction This study was performed to investigate the relationship between changes in urination-related quality of life (QOL) after brachytherapy and preoperative findings, including urinary function, urination scores, and patient background. Methods This retrospective study included 193 patients with localized prostate cancer who underwent brachytherapy at our institution. Urination-related QOL was assessed using the urinary domain of the Expanded Prostate Cancer Index Composite (EPIC) score, measured before treatment and 3, 6, and 12 months after treatment. Changes in EPIC scores from baseline were analyzed, and preoperative urination-related parameters - including prostate volume, maximum urinary flow rate, voiding volume, age, International Prostate Symptom Score (IPSS), and Overactive Bladder Symptom Score (OABSS) - were compared with post-treatment QOL outcomes. Results The urination-related EPIC score was lowest at three months post-treatment but gradually improved toward baseline levels. Patients with a preoperative voiding volume of <192 mL showed significantly greater declines in EPIC scores at 3, 6, and 12 months post-treatment. Additionally, those with an IPSS of <7 or an OABSS of <3 had significantly greater declines at six months, but these differences were not observed at 12 months. Prostate volume, maximum urinary flow rate, and age did not significantly impact changes in EPIC scores. Conclusion Preoperative voiding volume was significantly associated with changes in post-treatment urination-related QOL. These findings suggest that preoperative urination-related parameters may help predict post-treatment QOL, highlighting the importance of evaluating pretreatment urinary function when selecting treatments for patients with localized prostate cancer.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and Survival.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.